· SME · NSE
Price Band
₹196–208
Lot Size
600 shares
Issue Size
₹30 Cr
Min. Investment
₹1,24,800
Indicative, updates through the day
Cap price plus current GMP: ₹208 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Avience Biomedicals IPO is an SME issue that listed on NSE on 25 June 2026. The issue price band is fixed at ₹196–₹208 per equity share with a minimum market lot size of 600 shares, bringing the total issue size to ₹30 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹1,24,800.
No meaningful grey market premium is actively quoted for Avience Biomedicals IPO at this stage. For an SME issue at this point in the timeline, this is standard until anchor book allocations and institutional bids build volume. A missing premium is not negative sentiment; it reflects lower off-market liquidity. Read our complete guide to IPO GMP mechanics.
The minimum investment for retail investors is one lot of 600 shares (approx. ₹1,24,800 at the cut-off price). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is Skyline Financial Services Pvt. Ltd., with the basis of allotment finalised on 23 June 2026 and listing completed on 25 June 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹208
Listed At
₹395.2
Current Price
₹414.95
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees
Avience Biomedicals IPO raises ₹8.52 crore from anchor investors. Avience Biomedicals IPO Anchor bid date is June 17, 2026.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 6,83,400 | 49.83% |
| − Anchor Investor | 4,09,800 | 0% |
| − QIB (Ex. Anchor) | 2,73,600 | 0% |
| NII (HNI) | 2,07,000 | 15.09% |
| − bNII > ₹10L | 1,38,000 | 0% |
| − sNII < ₹10L | 69,000 | 0% |
| Retail | 4,81,200 | 35.08% |
| Market Maker | 82,200 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 1200 | ₹2,49,600 |
| Individual investors (IND) (Max) | 2 | 1200 | ₹2,49,600 |
| S-HNI (Min) | 3 | 1800 | ₹3,74,400 |
| S-HNI (Max) | 8 | 4800 | ₹9,98,400 |
| B-HNI (Min) | 9 | 5400 | ₹11,23,200 |
EPS (Pre IPO)
17.94
EPS (Post IPO)
12.56
ROE
22.38%
P/E (Pre IPO)
11.59
P/E (Post IPO)
16.56
Price / Book
2.94
Market Cap
₹84Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Anthem Biosciences Ltd. | 70.62 | ₹3,395.00 Cr |
Avience Biomedicals Ltd. Address
Skyline Financial Services Pvt. Ltd.